سعر املوسازيد 5/12.5/40 مجم 30 قرص 2024

Fixed-dose triple antihypertensive combination (Amlosazide, ATCO Pharma, Egypt): each film-coated tablet contains olmesartan medoxomil 40 mg, amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg; 30 tablets.

• Treatment of essential hypertension - add-on therapy: adults whose blood pressure is not adequately controlled on olmesartan medoxomil plus amlodipine taken as a dual-component formulation.Population: AdultsATCO Pharma (Egyptian manufacturer) - product insert leaflet
• Treatment of essential hypertension - substitution therapy: adults adequately controlled on olmesartan medoxomil, amlodipine and hydrochlorothiazide taken as a dual-component formulation (olmesartan/amlodipine or olmesartan/hydrochlorothiazide) plus a single-component formulation (hydrochlorothiazide or amlodipine).Population: AdultsATCO Pharma (Egyptian manufacturer) - product insert leaflet

• The most commonly reported adverse reactions with the triple combination are peripheral oedema, headache and dizziness.Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet

• Hypersensitivity to the active substances, to dihydropyridine derivatives, to sulfonamide-derived substances (hydrochlorothiazide is sulfonamide-derived) or to any excipient.Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet
• Severe renal impairment (creatinine clearance <30 mL/min).Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet
• Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet

• Symptomatic hypotension may occur in volume- and/or sodium-depleted patients (e.g. intensive diuretics, dietary salt restriction, diarrhoea, vomiting); correct before starting or monitor closely.Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet
• Patients whose renal function depends on the renin-angiotensin-aldosterone system (e.g. severe heart failure, renal artery stenosis) risk acute hypotension, azotaemia, oliguria or acute renal failure.Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet
• Dual blockade of the RAAS (ACE inhibitors, ARBs or aliskiren) is not recommended; ACE inhibitors and ARBs should not be used together in diabetic nephropathy.Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet

• LithiumReversible increases in lithium levels and toxicity (ARBs; thiazides reduce lithium clearance); combination not recommended; if necessary, monitor lithium levels carefully.ATCO Pharma (Egyptian manufacturer) - product insert leaflet
• NSAIDs (including aspirin >3 g/day and COX-2 inhibitors)May reduce the antihypertensive effect and increase the risk of renal impairment and hyperkalaemia.ATCO Pharma (Egyptian manufacturer) - product insert leaflet
• Potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, heparin, ACE inhibitorsMay increase serum potassium; monitor potassium.ATCO Pharma (Egyptian manufacturer) - product insert leaflet

• Contraindicated during pregnancy. For the olmesartan component, ARB exposure in the second and third trimesters is known to cause fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia); stop immediately when pregnancy is diagnosed. Hydrochlorothiazide crosses the placenta and in the 2nd/3rd trimester may compromise foetoplacental perfusion and cause foetal/neonatal icterus, electrolyte disturbance and thrombocytopenia. Limited amlodipine data do not indicate fetal harm, but delivery may be prolonged.Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet
• Not recommended during breastfeeding; alternatives with better established safety are preferable, especially for a newborn or preterm infant (if used, keep doses as low as possible). Amlodipine passes into human milk (estimated infant dose 3-7% of the maternal dose, maximum 15%); hydrochlorothiazide is excreted in small amounts and high doses may suppress lactation; olmesartan is excreted in rat milk (human data unknown).Egyptian label · ATCO Pharma (Egyptian manufacturer) - product insert leaflet

• Amlodipine: Inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, acting as a peripheral arterial vasodilator.
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.
• Olmesartan medoxomil: Prodrug hydrolysed to olmesartan, which blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II at the AT1 receptor.

Store at a temperature not exceeding 30 °C in a dry place; shelf life 2 years; carton of 1, 2 or 3 blisters of 10 film-coated tablets.